Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Shares Sold by Rice Hall James & Associates LLC

Rice Hall James & Associates LLC decreased its position in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) by 2.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 624,545 shares of the company's stock after selling 18,207 shares during the quarter. Rice Hall James & Associates LLC owned approximately 0.86% of Kiniksa Pharmaceuticals International worth $13,871,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. GAMMA Investing LLC grew its position in shares of Kiniksa Pharmaceuticals International by 84.8% during the 1st quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock worth $27,000 after buying an additional 568 shares in the last quarter. Asset Management One Co. Ltd. bought a new position in shares of Kiniksa Pharmaceuticals International during the 1st quarter worth $41,000. Wealthquest Corp bought a new position in shares of Kiniksa Pharmaceuticals International during the 1st quarter worth $42,000. Lazard Asset Management LLC purchased a new stake in shares of Kiniksa Pharmaceuticals International during the 4th quarter worth $61,000. Finally, KLP Kapitalforvaltning AS purchased a new stake in shares of Kiniksa Pharmaceuticals International during the 4th quarter worth $158,000. Institutional investors own 53.95% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on KNSA. Wedbush restated an "outperform" rating and set a $34.00 price objective on shares of Kiniksa Pharmaceuticals International in a research note on Wednesday, April 16th. Wall Street Zen upgraded Kiniksa Pharmaceuticals International from a "hold" rating to a "buy" rating in a research note on Sunday, July 6th. Wells Fargo & Company upped their price objective on Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the stock an "overweight" rating in a research note on Wednesday, July 9th. Finally, Jefferies Financial Group upped their price objective on Kiniksa Pharmaceuticals International from $40.00 to $45.00 and gave the stock a "buy" rating in a research note on Tuesday, April 29th. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $39.33.

Insider Transactions at Kiniksa Pharmaceuticals International

In related news, COO Eben Tessari sold 45,042 shares of the firm's stock in a transaction dated Wednesday, June 11th. The stock was sold at an average price of $30.51, for a total transaction of $1,374,231.42. Following the sale, the chief operating officer directly owned 72,363 shares of the company's stock, valued at $2,207,795.13. This trade represents a 38.36% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Mark Ragosa sold 21,254 shares of the firm's stock in a transaction dated Wednesday, April 30th. The stock was sold at an average price of $26.95, for a total value of $572,795.30. Following the sale, the chief financial officer directly owned 27,009 shares in the company, valued at approximately $727,892.55. This trade represents a 44.04% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 447,763 shares of company stock valued at $12,398,077 over the last three months. Company insiders own 53.48% of the company's stock.

Kiniksa Pharmaceuticals International Trading Up 1.5%

Shares of KNSA stock traded up $0.42 during mid-day trading on Thursday, reaching $28.84. The stock had a trading volume of 703,093 shares, compared to its average volume of 556,380. The business's fifty day moving average is $27.84 and its 200-day moving average is $23.39. The firm has a market cap of $2.10 billion, a price-to-earnings ratio of -115.36 and a beta of 0.05. Kiniksa Pharmaceuticals International, plc has a 1-year low of $17.82 and a 1-year high of $30.69.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The company reported $0.11 earnings per share for the quarter, beating analysts' consensus estimates of $0.02 by $0.09. The business had revenue of $137.79 million for the quarter, compared to analyst estimates of $128.35 million. Kiniksa Pharmaceuticals International had a negative return on equity of 3.83% and a negative net margin of 3.52%. The company's revenue was up 72.5% on a year-over-year basis. During the same period in the prior year, the company earned ($0.25) earnings per share. On average, analysts forecast that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current year.

Kiniksa Pharmaceuticals International Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.